---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022910"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:55:57.343310+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics Q3 net loss $23.7M; cash $221.8M; selected 12mg dose for FTX-6058 SCD trial

## Summary
- Net loss $23.7M vs $20.7M year ago; collaboration revenue fell to $1.2M from $4.9M due to Acceleron wind-down.
- Cash, equivalents, and marketable securities $221.8M; cash runway guidance extended into late 2024.
- Completed equity raise of ~$80.8M net proceeds in August 2022.
- Selected 12mg as dose for next FTX-6058 Phase 1b cohort in sickle cell disease; enrollment continues.
- Appointed Santiago Arroyo as CMO and Jeff Jacobs as CSO; losmapimod Phase 3 REACH trial enrollment ongoing.

## SEC filing metadata
- accession: 0000950170-22-022910
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017022022910/0000950170-22-022910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017022022910/fulc-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022910
- JSON: https://secwatch.observer/filing/0000950170-22-022910.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022910.txt

## Key facts
- Earnings Releases
  Fulcrum Therapeutics, Inc. reported the third quarter of 2022 results: revenue $1.2 million, net income Net loss was $23.7 million.
  - Period: the third quarter of 2022
  - Revenue: $1.2 million
  - Net income: Net loss was $23.7 million
  - Result: reported results
  source text: Third Quarter 2022 Financial Results • Cash Position: As of September 30, 2022, cash, cash equivalents, and marketable securities were $221.8 million as compared to $218.2 million as of December 31, 2021. The increase in cash is primarily tied to our equity offering in August 2022, partially offset by our net cash used in operating activities. • Collaboration Revenue: Collaboration revenue was $1.2 million for the third quarter of 2022 as compared to $4.9 million for the third quarter of 2021. The decrease of $3.7 million was primarily due to the winding down of Fulcrum's collaboration agreement with Acceleron Pharma Inc., a wholly owned subsidiary of Merck & Co., Inc. • Operating Expenses: Total operating expenses were $25.5 million for the third quarter of 2022 as compared to $25.7 million for the third quarter of 2021. A decrease of $1.7 million in R&D expenses was primarily due to reduced discovery and external research and development costs. This was partially offset by an increas
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000095017022022910/0000950170-22-022910-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.